Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
2(22%)
Results Posted
67%(4 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
3
33%
Ph phase_2
4
44%
Ph phase_3
2
22%

Phase Distribution

3

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 24 (44.4%)
Phase 32 (22.2%)

Trials by Status

terminated111%
recruiting111%
active_not_recruiting111%
completed667%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180
active_not_recruitingphase_2

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT03485209
terminatedphase_1

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

NCT03786081
completedphase_3

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

NCT04697628
completedphase_1

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

NCT05866354
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06459180Phase 3

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

Recruiting
NCT03485209Phase 2

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active Not Recruiting
NCT03786081Phase 1

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Terminated
NCT04697628Phase 3

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Completed
NCT05866354Phase 1

To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Completed
NCT03438396Phase 2

A Trial of Tisotumab Vedotin in Cervical Cancer

Completed
NCT03657043Phase 2

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Completed
NCT03913741Phase 1

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Completed
NCT03245736Phase 2

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Completed

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9